Bausch + Lomb (BLCO)

Search documents
Bausch + Lomb (BLCO) - 2022 Q4 - Earnings Call Transcript
2023-02-22 18:41
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2022 Earnings Conference Call February 22, 2023 8:00 AM ET Company Participants Art Shannon – Investor Relations Joe Papa – Chief Executive Officer Brent Saunders – Incoming Chief Executive Officer and Chairman of the Board of Directors Sam Eldessouky – Executive Vice President and Chief Financial Officer Conference Call Participants Craig Bijou – Bank of America Cecilia Furlong – Morgan Stanley Matt Miksic – Barclays Vijay Kumar – Evercore ISI Joanne Wuensch – Citi ...
Bausch + Lomb (BLCO) - 2022 Q4 - Earnings Call Presentation
2023-02-22 12:54
BAUSCH+LOMB This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forwardlooking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2023 first quarter outlook and assumption thereof), the planned spin-off or separation of the Company from Bausch Health Companies Inc. ("BHC ...
Bausch + Lomb (BLCO) - 2022 Q4 - Annual Report
2023-02-21 16:00
Bausch + Lomb Corporation (Exact Name of Registrant as Specified in its Charter) Canada 98-1613662 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________ FORM 10-K Commission File Number: 001-41380 Registrant's telephone number, including area code (905) 695-7700 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Shares, No Par ...
Bausch + Lomb (BLCO) Presents At 41st Annual Healthcare Conference - Slideshow
2023-01-20 13:03
1. Third party market research and management estimates. Contact lens includes: sales from contact lenses, lens care solutions, and off-the-shelf eye care products; Consumer includes: sales from eye drops and eye vitamins 2. Third party market research and management estimates. AMD includes: sales from products for the treatment of wet age-related macular degeneration ("AMD") and dry AMD; Glaucoma includes: sales from products for the treatment of glaucoma; Dry Eye / Other includes: sales from products for ...
Bausch + Lomb (BLCO) - 2022 Q3 - Earnings Call Presentation
2022-11-06 16:48
3Q22 Financial Results Forward-Looking Statements 1 This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forwardlooking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2022 full-year guidance, expectations regarding adjusted gross margin and expected organic growth), t ...
Bausch + Lomb (BLCO) - 2022 Q3 - Earnings Call Transcript
2022-11-06 16:45
Bausch + Lomb Corporation (NYSE:BLCO) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Alison Ryan - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Zack Weiner - Jefferies Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Craig Bijou - Bank of America Larry Biegelsen - Wells Fargo Pito Chickering - Deutsche Bank Operator Good morning, and welcome to the Bausch + ...
Bausch + Lomb (BLCO) - 2022 Q3 - Quarterly Report
2022-11-01 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other ...
Bausch + Lomb (BLCO) - 2022 Q2 - Earnings Call Presentation
2022-08-07 07:04
2Q22 Financial Results Forward-Looking Statements 1 This presentation contains forward-looking information and statements, within the meaning of applicable securities laws (collectively, "forwardlooking statements"), including, but not limited to, statements regarding future prospects and performance of Bausch + Lomb Corporation ("Bausch + Lomb", the "Company", "we", "us", or "B+L") (including the Company's 2022 full-year guidance, expectations regarding adjusted gross margin and expected organic growth), t ...
Bausch + Lomb (BLCO) - 2022 Q2 - Earnings Call Transcript
2022-08-07 07:01
Bausch + Lomb Corporation (NYSE:BLCO) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Arthur Shannon - Investor Relations Joseph Papa - Chief Executive Officer Sam Eldessouky - Executive Vice President and Chief Financial Officer Conference Call Participants Joanne Wuensch - Citi Craig Bijou - Bank of America Imron Zafar - Deutsche Bank Doug Miehm - RBC Capital Markets Yatin Suneja - Guggenheim Partners Cecilia Furlong - Morgan Stanley Vijay Kumar - Evercore Zack Weiner - Jef ...
Bausch + Lomb (BLCO) - 2022 Q2 - Quarterly Report
2022-08-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File Number: 001-41380 Bausch + Lomb Corporation (Exact name of registrant as specified in its charter) Canada 98-1613662 (State or other juri ...